4//SEC Filing
Tatsis Ourania 4
Accession 0000875320-25-000244
CIK 0000875320other
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 4:12 PM ET
Size
5.2 KB
Accession
0000875320-25-000244
Insider Transaction Report
Form 4
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
Transactions
- Sale
Common Stock
2025-12-03$449.99/sh−4,500$2,024,955→ 46,793 total
Footnotes (3)
- [F1]Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.
- [F2]Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00).
- [F3]Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001789815
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 4:12 PM ET
- Size
- 5.2 KB